Ballentine Partners, LLC Theravance Biopharma, Inc. Transaction History
Ballentine Partners, LLC
- $6.57 Billion
- Q2 2025
A detailed history of Ballentine Partners, LLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 14,315 shares of TBPH stock, worth $166,340. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,315
Previous 13,094
9.32%
Holding current value
$166,340
Previous $116,000
35.34%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TBPH
# of Institutions
137Shares Held
47.3MCall Options Held
700Put Options Held
1.4K-
Madison Avenue Partners, LP New York, NY9.51MShares$111 Million10.97% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$86.7 Million1.9% of portfolio
-
Newtyn Management, LLC New York, NY4.76MShares$55.3 Million8.37% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$43.9 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$32.1 Million3.74% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $776M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...